Certificate under Regulation 74(5) of SEBI (DP) Regulation 2018 for the quarter ended March 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Pharmaids Pharmaceuticals has submitted a routine quarterly compliance certificate to BSE for Q4 FY25 (quarter ended March 31, 2025). The certificate, issued by the company's Registrar and Share Transfer Agent (RTA) — Venture Capital and Corporate Investments Pvt Ltd — confirms that all physical share certificates received for dematerialization during the quarter were properly mutilated and cancelled after due verification. The names of NSDL and CDSL have been updated in the company's records as the registered owners of those shares within the SEBI-mandated 15-day timeline. This is a standard regulatory requirement under the SEBI (Depositories and Participants) Regulations, 2018.
No material impact on shareholders or the stock price. This is a routine housekeeping filing that simply confirms the company's share dematerialization process is working as required by SEBI rules.